Kelly Oakley CTA is an associate director at incentives and reliefs specialist, ForrestBrown.
After a period defined by rapid reform, 2026 brings something relatively rare to the R&D tax landscape: stability. For advisers who have spent recent years navigating shifting guidance, updated legislation and evolving compliance expectations, this pause is welcome. But stability should not be mistaken for simplicity. In practice, many of the reforms introduced over the past two years are only now beginning to bed in – and advisers cannot afford to be on the back foot.
Restrictions on overseas R&D expenditure, tighter rules around contracted-out work and reduced SME rates remain very real headwinds. HMRC’s interpretation of these changes has not yet been fully tested through enquiry, raising the stakes for accuracy and documentation. At the same time, the merged R&D scheme has removed longstanding limitations for grant-funded projects, allowing businesses more scope to combine incentives than in the past. This requires a more proactive approach to unlocking value.
Sector focus, short windows
One of the most significant shifts this year is the renewed alignment between government policy and the incentives that support it. The Modern Industrial Strategy identifies eight high potential growth sectors expected to drive investment across the UK economy. For clients working within these focus areas, the funding environment is promising. But the pace of grant activity – with application windows often just a few weeks long – means that being “bid ready” is now a fundamental requirement rather than a nice to have.
Advisers who can anticipate which projects align with specific competitions, and ensure that financials and project narratives are ready ahead of time, offer their clients a genuine competitive edge. On the flipside, businesses that miss out may do so as a result of flaws in their process rather than fundamental project weakness.
Lifecycle funding decisions
A common thread across all successful funding strategies is effective sequencing. Each incentive plays a distinct role in the innovation lifecycle:
- Grants can derisk early stage or technically ambitious work.
- R&D tax relief recovers historic technical expenditure, strengthening cashflow.
- Innovation loans support late-stage development, scaleup and commercialisation.
- Patent Box reduces the tax rate applied to profits derived from patented IP.
This is not a menu to choose from; it is a toolkit to be deployed at the right time. Understanding where a client sits in its development journey is essential to selecting the right mechanism. A startup exploring feasibility is not facing the same funding questions as an established business about to enter regulated trials. Advisers can add value by helping clients identify the right tool at the right time.
Unlocking the “last mile” of development
For projects approaching commercialisation, where capital is tied up in tooling, certification, testing, supply chain onboarding or first production runs, innovation loans can be an effective solution. They offer patient, flexible capital at below-market rates at a time when accessing funding can be challenging.
Innovation loans can stretch a business’s funding runway, protect cash reserves and accelerate time to market – all while fitting neatly into a wider incentives strategy. Yet identifying eligibility requires forward visibility of clients’ technical roadmaps. Those conversations need to be happening early and often.
Further along the journey, Patent Box remains one of the UK’s most powerful tax levers for innovative businesses. While often underutilised, it can materially influence investment decisions, particularly for companies operating in highly technical sectors where IP is central to growth strategy.
How advisers can add value
Beyond identifying funding opportunities, advisers have a central role to play in guiding clients through the application or claim process, and ensuring methodologies stand up under the scrutiny of compliance and due diligence checks.
High quality recordkeeping, for example, is no longer simply good practice. It is the foundation for credible grant submissions, robust R&D claims and futureproofed Patent Box elections. Evidence trails are also critical for due diligence checks, particularly where grants involve third party assessors. Advisers can make a measurable difference by embedding these disciplines into routine reporting cycles rather than treating them as project-specific exercises.
Strong forecasting adds a further layer of resilience. By modelling how grants, R&D claims, loan drawdowns and Patent Box benefits interact, advisers can help clients understand the combined cashflow impact of their choices. This allows leaders to plan confidently, avoid overreliance on any single funding source and build multiyear strategies that support sustained investment in innovation.
Three actions advisers should take now:
1. Review your client portfolio through a 2026 lens
Look at clients’ projects, sectors and timelines. Identify those aligned with priority areas and begin preparing evidence ahead of competition windows.
2. Assess which clients are “loan ready”
Projects nearing the final development hurdle should be evaluated for innovation loan suitability. Timing is critical; don’t wait for clients to ask.
3. Embed audit ready processes
Encourage clients to maintain coherent, centralised data trails across all incentive streams. This reduces compliance risk and strengthens every subsequent claim or application.
A year of innovation?
2026 offers the chance to step back, consolidate understanding and build funding strategies that are both ambitious and robust. By taking a holistic, lifecycle view of the incentives landscape, advisers can help clients navigate complexity with confidence – and ultimately support them in turning innovative ideas into commercial success. In doing so, advisers not only enhance the value they provide, but position themselves at the centre of the UK’s broader ambition to build a stronger, more competitive, innovation-driven economy.
